Publications by authors named "Mathilde Frechet Jachym"
Definitions of resistance in multidrug-resistant tuberculosis (MDR TB) and extensively drug-resistant tuberculosis (XDR TB) have been updated. Pre-XDR TB, defined as MDR TB with additional resistance to fluoroquinolones, and XDR TB, with additional resistance to bedaquiline or linezolid, are frequently associated with treatment failure and toxicity. We retrospectively determined the effects of pre-XDR/XDR TB resistance on outcomes and safety of MDR TB treatment in France.
View Article and Find Full Text PDFArticle Synopsis
- - The study investigates the diagnosis and treatment outcomes of multidrug-resistant osteoarticular tuberculosis (MDR-OATB) in France, based on a review of 23 cases from 2007 to 2018.
- - Most affected patients were young males, with the spine being the most common site of infection; a significant portion had prior tuberculosis treatments.
- - Despite a high treatment success rate (91%) achieved with a mean regimen of four drugs over approximately 20 months, the ideal treatment protocol for MDR-OATB, including drug combinations and surgical options, is still not established.
Article Synopsis
- The study investigates the correlation between linezolid drug levels and the occurrence of severe toxicity in patients being treated for multidrug-resistant tuberculosis (MDR TB) from 2011 to 2017.
- Severe mitochondrial toxicity was found in 39% of the 146 patients, with higher drug concentrations linked to increased risk of neurotoxicity or myelotoxicity.
- The results suggest that patients with linezolid trough concentrations above 2 mg/L have a significantly higher chance of developing severe side effects, highlighting the need for careful monitoring and risk evaluation in treatment decisions.
Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78% (95% CI 73.
View Article and Find Full Text PDFBackground: Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed to estimate the association of treatment success and death with the use of individual drugs, and the optimal number and duration of treatment with those drugs in patients with multidrug-resistant tuberculosis.
Methods: In this individual patient data meta-analysis, we searched MEDLINE, Embase, and the Cochrane Library to identify potentially eligible observational and experimental studies published between Jan 1, 2009, and April 30, 2016.
Bedaquiline, a recently approved drug for the treatment of multidrug-resistant tuberculosis (MDR-TB), is recommended for a duration of 24 weeks. There are scarce data on patients treated with this drug outside clinical trials.All MDR-TB patients who started treatment from January 1, 2011 to December 31, 2013 and received ≥30 days of bedaquiline were included in a multicentre observational cohort.
View Article and Find Full Text PDF